Latest press releases

September 21, 2023

Stayble Therapeutics presents at Financial Stockholm’s investor meeting on September 25, 2023

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company will participate in the investor meeting “Investera som proffsen,” organized by Financial Stockholm on September 25, 2023.

Read more
September 6, 2023

Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study

Stayble Therapeutics AB (“Stayble” or the “Company”) today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc disease has been completed.  This means that the target number of evaluable patients in the study has now been reached twelve months after receiving treatment with STA363. The Phase 2b study, aimed at evaluating the pain relief of the drug candidate STA363, has been successfully concluded with high quality, good compliance and a low patient dropout rate. The company is following the previously communicated timeline and expects to communicate top line results in the fourth quarter of 2023.

Read more
September 6, 2023 Regulatorisk

Stayble Therapeutics terminates agreement regarding liquidity provider

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB (“Lago”). The agreement will cease to be effective on September 29, 2023.

Read more
August 28, 2023

First patient enrolled in Stayble Therapeutics’ Phase 1b clinical study in herniated discs

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the first patient has been enrolled in the Company’s Phase 1b clinical study with STA363 for treatment of herniated discs. STA363 for Herniated discs is the second indication for the drug candidate STA363, which is also undergoing a clinical study in degenerative disc disease. Stayble has successfully completed a Phase 1b study in degenerative disc disease and is currently in the final phase of an ongoing Phase 2b study.

Read more

Press photos

In need of press photos? Contact us for a curated collection of images and logotypes approved for use in editorial purposes.

press@stayble.se

Upcoming events

No events planned at the moment

Archived events

8March2023

Life-Sciencedagen in Gothenburg March 8 at 17.00

Read more
1December2022

CEO present at Pro-hearing in Stockholm 1 December

Read more
8November2022

CEO present at Aktiedagen Göteborg 8 November 11.00-11.30

Read more
18October2022

BioStock Investor Pitch 18 Oktober at 10am

Read more

LATEST ARTICLES AND COMPANY ANALYSIS

INVEST IN THE FUTURE TREATMENT OF CHRONIC BACK AND LEG PAIN

Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.

Investors